Abstract
Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Current Molecular Pharmacology
Title:Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Volume: 5
Author(s): Ulf Krause and Carl A. Gregory
Affiliation:
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Abstract: Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Export Options
About this article
Cite this article as:
Krause Ulf and A. Gregory Carl, Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent, Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020164
DOI https://dx.doi.org/10.2174/1874467211205020164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Trans-Platinum Complexes with Promising Antitumor Properties
Medicinal Chemistry Reviews - Online (Discontinued) Antioxidant Response of Osteoblasts to Doxycycline in an Inflammatory Model Induced by C-reactive Protein and Interleukin-6
Infectious Disorders - Drug Targets Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models?
Current Cancer Drug Targets Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Nanomedical Platform for Drug Delivery in Cancer
Current Organic Chemistry Characterization of β-Sitosterol for Potential Selective GR Modulation
Protein & Peptide Letters Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Role of Nanoparticles in Drug Delivery and Regenerative Therapy for Bone Diseases
Current Drug Delivery Synthesis of Phenol-derivatives and Biological Screening for Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets